Streetbeat News

Regulatory

GOVX

GeoVax Labs, Inc. (NASDAQ:GOVX) presented Phase 1/2 clinical trial data for its gene therapy candidate, Gedeptin, at the AACR-AHNS Head and Neck Cancer Conference. The ongoing trial is evaluating the safety and efficacy of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma. The study, funded in part by the FDA, has shown no serious adverse events and evidence of a reduction in tumor size. GeoVax anticipates completion of the trial by the end of 2023.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 1:03 pm

SISI

Shineco, Inc. (NASDAQ:SISI) announced that its subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., received marketing and distribution approval from China's National Medical Products Administration (NMPA) for its Cardiac 5-Minute Test. The test, which can detect three major cardiac markers in one test, is the first and only product on the market in China to complete the detection process for cardiac markers within 5 minutes. The approval is expected to support Biowin's business development efforts in the Point-of-Care Testing industry.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 1:02 pm

SIVBQ

SVB Financial Group has filed a lawsuit against the U.S. Federal Deposit Insurance Corporation (FDIC) to recover $1.93 billion that was seized during the takeover of Silicon Valley Bank in March. The FDIC claims that SVB Financial's failure reduced its insurance fund by $16 billion and it can legally hold the seized funds. The bank is facing reorganization-related issues due to a lack of funds.

Portfolio Pulse from Lekha Gupta

July 10, 2023 | 12:55 pm

NXL

Nexalin Technology's abstract on its non-invasive, frequency-based deep-brain stimulation device for treating mild traumatic brain injury (mTBI) has been accepted for presentation at the 2023 Military Health System Research Symposium. The abstract details a study using Magnetoencephalography (MEG) to assess neuronal changes in veterans with combat-related mTBI after treatment with Nexalin's device. The data supports Nexalin's strategy to offer a new tool to treat mTBI without medication or side effects. A prior study also showed significant improvements in patients with chronic insomnia using Nexalin's device.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:39 pm

INFI

Infinity Pharmaceuticals (NASDAQ:INFI) has provided further details on its Phase 2 MARIO-8 study evaluating eganelisib in combination with pembrolizumab in patients with squamous cell cancer of the head and neck. The adaptive design of the study aims to optimize the dose of eganelisib. Preliminary safety and efficacy data are expected in the second half of 2024. The company is also progressing towards a merger with MEI Pharma, which has been recommended by two leading independent proxy advisory firms.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:31 pm

PBLA

Panbela Therapeutics, Inc. (NASDAQ:PBLA) announces that the independent Data Safety Monitoring Board (DSMB) of the Phase III ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has recommended that the study continue without modification. The ASPIRE Trial is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The company's pipeline consists of assets currently in clinical trials with an initial focus on familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention and ovarian cancer.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:17 pm

AIM

AIM ImmunoTech Inc. has enrolled and dosed the first subject in its Phase 2 study evaluating Ampligen as a potential treatment for post-COVID conditions. The study, expected to be completed in Q4 2023, is a major milestone for the company. Preliminary data suggests Ampligen could be an effective treatment option for post-COVID conditions. The study will enroll approximately 80 subjects aged 18 to 60 years across up to 10 centers in the United States.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:13 pm

BIVI

BioVie Inc. (NASDAQ:BIVI) will present data at the Alzheimer's Associate's International Conference showing how its drug candidate NE3107 regulates specific genes in a manner correlated with cognitive and biomarker improvements. The drug has shown potential in reducing DNA methylation, which is associated with various diseases. The data suggests that NE3107 may change the degree to which specific genes are epigenetically regulated, with potential functional correlations to cognition, inflammation, and Alzheimer's biomarkers.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:11 pm

BABA

Alibaba Group Holding Limited (NYSE:BABA) is considering selling shares of Ant Group back to the fintech company, which has proposed a $6 billion share repurchase program. Alibaba, which holds a 33% stake in Ant, proposes to transfer any repurchased shares into the fintech company's employee incentive plan. Ant Group's valuation has declined by nearly 70% compared to its market capitalization during its IPO, which China scrapped in 2020. The company faces challenges in regaining its former valuation and operations despite the regulatory crackdown ending.

Portfolio Pulse from Anusuya Lahiri

July 10, 2023 | 12:11 pm

ASML

BABA

NVDA

TSM

Alibaba's Youku platform is set to air a series called 'My Chinese Chip' that focuses on China's semiconductor self-sufficiency. The series highlights the challenges faced by a domestic company in overcoming trade sanctions and technological restrictions that prevent the acquisition of advanced chipmaking technology. The series also depicts the trade war between the U.S. and China, which has led to restrictions on the sale of advanced chipmaking equipment, particularly from ASML Holding NV. The restrictions have underscored China's need to enhance its self-sufficiency and develop domestic capabilities to meet its semiconductor demands.

Portfolio Pulse from Anusuya Lahiri

July 10, 2023 | 12:08 pm